Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 12 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.07 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 802.56% year-over-year to $0.07; the TTM value through Dec 2025 reached -$0.28, down 180.0%, while the annual FY2025 figure was -$0.28, 211.11% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.07 in Q4 2025 per LCTX's latest filing, up from -$0.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.07 in Q4 2025 and bottomed at -$0.13 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.04, with a median of -$0.03 recorded in 2021.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 802.56% in 2025, down 550.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.05 in 2021, then fell by 10.64% to -$0.06 in 2022, then surged by 50.0% to -$0.03 in 2023, then soared by 66.67% to -$0.01 in 2024, then surged by 802.56% to $0.07 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.07 in Q4 2025, -$0.13 in Q3 2025, and -$0.13 in Q2 2025.